NEWS
Aclaris Therapeutics Announces Sale of OLUMIANT® Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million
Aclaris Therapeutics (NASDAQ: ACRS) has announced the sale of a portion of its future royalty payments and certain milestones for OLUMIANT® (baricitinib) to OMERS Life Sciences for up to $31.5 million. The deal includes a $26.5 million upfront payment and up to $5.0 million in potential milestone payments based on OLUMIANT sales in 2024. This non-dilutive transaction strengthens Aclaris' balance sheet, providing financial flexibility to pursue value-creating opportunities and invest in internal programs. OMERS acquires a portion of the royalty for worldwide net sales of OLUMIANT for alopecia areata from April 1, 2024, through the remainder of the royalty term, as well as 100% of the remaining anniversary milestone payments from Eli Lilly.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1074Followers
68Following
7372Visitors
Follow